In the ICE-AFIB Trial, patients who received concomitant Cox-Maze III lesions using the cryoICE cryoFORM® Cryoablation probe during cardiac surgery experienced improvements in quality of life.*

Mean QoL scores* improved by +32.0 at 12 months (95% CI: 27.3, 36.6) and by +32.6 at 24 months (95% CI: 27.6, 37.6) compared to baseline – demonstrating durable benefit over time.

Read the full study: <a href="https://okt.to/eLRrSY&quot; target="_blank">https://okt.to/eLRrSY</a&gt;

*As calculated from the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. A 5-point change is considered clinically meaningful.